{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:22:23Z","timestamp":1761060143252},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8,1]]},"DOI":"10.1093\/jjco\/hyw071","type":"journal-article","created":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T23:03:37Z","timestamp":1465254217000},"page":"775-780","source":"Crossref","is-referenced-by-count":11,"title":["Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy"],"prefix":"10.1093","volume":"46","author":[{"given":"Keita","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyasu","family":"Matsuyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakanori","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Nagao","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,8,2]]},"reference":[{"key":"key\n\t\t\t\t2018111910523582400_hyw071C1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00005392-200101000-00012","article-title":"De novo muscle invasive bladder cancer: is there a change in trend","volume":"165","author":"Vaidya","year":"2001","journal-title":"J Urol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C3","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(03)13580-5","article-title":"Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis","volume":"361","year":"2003","journal-title":"Lancet (London, England)"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C4","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.28655","article-title":"Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma","volume":"120","author":"Porten","year":"2014","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C5","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"10","author":"Loehrer","year":"1992","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C6","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7","article-title":"Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse","volume":"64","author":"Sternberg","year":"1989","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C7","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C8","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.1997.15.2.589","article-title":"Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma","volume":"15","author":"Witte","year":"1997","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C10","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1200\/JCO.1997.15.5.1853","article-title":"Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma","volume":"15","author":"McCaffrey","year":"1997","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C11","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.3816\/CGC.2009.n.018","article-title":"Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study","volume":"7","author":"Joly","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/jjco\/hym011","article-title":"Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after cisplatin-containing therapy: a Japanese experience","volume":"37","author":"Akaza","year":"2007","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/(SICI)1097-0142(19990801)86:3<514::AID-CNCR21>3.0.CO;2-9","article-title":"A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium","volume":"86","author":"Sweeney","year":"1999","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005392-200101000-00017","article-title":"Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study","volume":"165","author":"Krege","year":"2001","journal-title":"J Urol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1742-1241.2005.00663.x","article-title":"Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20\/99)","volume":"60","author":"Fechner","year":"2006","journal-title":"Int J Clin Pract"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00280-005-0175-4","article-title":"Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy","volume":"58","author":"Shinohara","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C17","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1349-7006.2011.01909.x","article-title":"Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group","volume":"102","author":"Kitamura","year":"2011","journal-title":"Cancer Sci"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C18","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.eururo.2013.11.046","article-title":"EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines","volume":"65","author":"Witjes","year":"2014","journal-title":"Eur Urol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C19","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","article-title":"Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract","volume":"27","author":"Bellmunt","year":"2009","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C20","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/cncr.24313","article-title":"Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma","volume":"115","author":"Calabro","year":"2009","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jjco\/hyp003","article-title":"Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma","volume":"39","author":"Suyama","year":"2009","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C22","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s10147-008-0779-x","article-title":"Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy","volume":"13","author":"Kanai","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C23","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2002.20.4.937","article-title":"Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer","volume":"20","author":"Vaughn","year":"2002","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0378-4274(90)90161-E","article-title":"Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices","volume":"52","author":"Kameyama","year":"1990","journal-title":"Toxicol Lett"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/CMAR.S35785","article-title":"Nedaplatin: a cisplatin derivative in cancer chemotherapy","volume":"5","author":"Shimada","year":"2013","journal-title":"Cancer Manag Res"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C26","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1006\/gyno.1998.5140","article-title":"In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers","volume":"71","author":"Monk","year":"1998","journal-title":"Gynecol Oncol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C27","first-page":"305","article-title":"Clinical applications of the histoculture drug response assay","volume":"1","author":"Furukawa","year":"1995","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C28","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1442-2042.2011.02913.x","article-title":"Influence of baseline renal function and dose reduction of nephrotoxic chemotherapeutic agents on the outcome of metastatic urothelial carcinoma: a retrospective study","volume":"19","author":"Maru","year":"2012","journal-title":"Int J Urol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/ajco.12093","article-title":"Relative dose intensity in early stage breast cancer chemotherapy: A retrospective analysis of incidence, risk factors and outcomes at a south-west Sydney cancer clinic","volume":"9","author":"Sandy","year":"2013","journal-title":"Asia-Pac J Clin Oncol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C31","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ygyno.2011.05.023","article-title":"Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer","volume":"122","author":"Fauci","year":"2011","journal-title":"Gynecol Oncol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C32","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.juro.2013.11.004","article-title":"Outcome of metastasectomy for urothelial carcinoma: a multi-institutional retrospective study in Japan","volume":"191","author":"Abe","year":"2014","journal-title":"J Urol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C33","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11255-016-1226-y","article-title":"Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies","volume":"48","author":"Tonyali","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/1756287215597647","article-title":"Targeting PD-1\/PD-L1 in the treatment of metastatic renal cell carcinoma","volume":"7","author":"Weinstock","year":"2015","journal-title":"Ther Adv Urol"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C35","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018111910523582400_hyw071C36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/46\/8\/775\/26649953\/hyw071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T05:34:08Z","timestamp":1568007248000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/46\/8\/775\/1751433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,1]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8,2]]},"published-print":{"date-parts":[[2016,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyw071","relation":{},"ISSN":["1465-3621","0368-2811"],"issn-type":[{"value":"1465-3621","type":"electronic"},{"value":"0368-2811","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,8]]},"published":{"date-parts":[[2016,8,1]]}}}